Arvinas, Inc.
Arvinas, Inc., a pioneering biotechnology company headquartered in the United States, is at the forefront of developing innovative therapies through its proprietary PROTAC® (Proteolysis Targeting Chimera) technology. Founded in 2013, Arvinas has made significant strides in the biopharmaceutical industry, focusing on targeted protein degradation to address unmet medical needs in oncology and other serious diseases. With a strong operational presence in key regions across the US, Arvinas is dedicated to advancing its pipeline of drug candidates, which uniquely harness the body's natural degradation mechanisms to eliminate disease-causing proteins. The company has garnered attention for its strategic partnerships and collaborations, positioning itself as a leader in the field of targeted therapies. Arvinas continues to push the boundaries of science, aiming to transform the treatment landscape for patients worldwide.
DitchCarbon Score
How does Arvinas, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Arvinas, Inc.'s score of 25 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Arvinas, Inc.'s reported carbon emissions
Arvinas, Inc., headquartered in the US, currently does not have any publicly available carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges from the company. As a result, Arvinas has not established any formal commitments to reduce emissions or align with science-based targets. The lack of emissions data and reduction initiatives suggests that the company may still be in the early stages of developing its climate strategy. In the context of the biotechnology industry, where sustainability is increasingly becoming a priority, Arvinas may need to consider implementing robust climate commitments to enhance its environmental performance and align with industry standards.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Arvinas, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
